Clinical Trials Logo

Poliomyelitis clinical trials

View clinical trials related to Poliomyelitis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06442449 Not yet recruiting - Poliomyelitis Clinical Trials

Booster Dose of sIPV Co-administered With MMR and HepA-I.

Start date: July 10, 2024
Phase: Phase 4
Study type: Interventional

This is an Open-labeled, Randomized, Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of Booster Dose of Sabin Strain Inactivated Poliovirus Vaccine (Vero cell) (sIPV) Co-administered with Measles, Mumps, Rubella (MMR) Combined Live Attenuated Vaccine and Inactivated Hepatitis A (Hep-A) Vaccine.

NCT ID: NCT06346834 Not yet recruiting - Poliomyelitis Clinical Trials

Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains From Different Manufacturers

Start date: April 30, 2024
Phase: Phase 4
Study type: Interventional

To evaluate the immunogenicity and safety of sequential vaccination with Sinovac sIPV among infants who have received two doses of Biological Products Co., Ltd. sIPV.

NCT ID: NCT06137664 Not yet recruiting - Poliomyelitis Clinical Trials

Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines

Start date: March 29, 2025
Phase: Phase 1/Phase 2
Study type: Interventional

The main objectives of this study are to : - evaluate the safety and tolerability of trivalent novel oral poliovirus vaccines (tnOPV) in healthy adults, young children, and neonates, relative to those receiving control vaccines; - evaluate the safety and tolerability of combined novel oral poliovirus vaccine type 1 (nOPV1) + novel oral poliovirus vaccine type 2 (nOPV2) in neonates, relative to those receiving the bivalent (types 1 and 3) oral poliovirus vaccine (bOPV) control. - compare type-specific antibody responses among all tnOPV dose combinations, following 4 vaccinations in healthy neonates; - evaluate the type-specific and overall antibody response among healthy neonates following 4 doses of combined nOPV1+nOPV2.

NCT ID: NCT05952596 Not yet recruiting - Hepatitis B Clinical Trials

A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults

Start date: July 17, 2023
Phase: Phase 1
Study type: Interventional

This is a single-center, randomized, active-controlled, parallel-design, double-blind, phase I study to evaluate the safety and immunogenicity of a single dose of APV006 in healthy adults.

NCT ID: NCT05457946 Not yet recruiting - Hepatitis B Clinical Trials

Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series

Start date: April 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate immunogenicity and safety of different doses of candidate hexavalent vaccine in comparison to co-administration of Pentavalent vaccine and Poliomyelitis Vaccine (Inactivated) in separate injections at four weeks after completion of three-dose primary series at 6-10-14 weeks of age when administered to healthy infants and thereby to select the optimal dose of candidate vaccine(Stage 1) and to demonstrate lot-to-lot consistency of three lots of LBVD (Stage 2)

NCT ID: NCT04073459 Not yet recruiting - Hepatitis B Clinical Trials

Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants

Start date: November 2019
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate immunogenicity and safety of three different doses of candidate hexvalent vaccine in comparison to co-administration of EupentaTM Inj. and Imovax® Polio in separate injections at four weeks after completion of three-dose primary series at 6-10-14 weeks of age when administered to healthy infants and thereby to select the optimal dose of candidate vaccine